BGLC vs QDEL vs CLOV vs RNAZ vs AEYE

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). Analysts rate QuidelOrtho Corporation (QDEL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AudioEye, Inc.

(AEYE) delivered a total return of -60. 2%, compared to -100. 0% for TransCode Therapeutics, Inc. (RNAZ). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus RNAZ's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TransCode Therapeutics, Inc.

(RNAZ) is the lower-risk stock at 0. 80β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 186% more volatile than RNAZ relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: TransCode Therapeutics, Inc. grew EPS 98. 6% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TransCode Therapeutics, Inc.

(RNAZ) is the more profitable company, earning 0. 0% net margin versus -41. 5% for QuidelOrtho Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNAZ leads at 0. 0% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

4x forward P/E versus 88. 1x for Clover Health Investments, Corp. — 81. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QDEL: 57. 8% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, TransCode Therapeutics, Inc.

(RNAZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80)). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNAZ: -100. 0%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BGLC (Healthcare) and QDEL (Healthcare) and CLOV (Healthcare) and RNAZ (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BGLC is a small-cap quality compounder stock; QDEL is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock; RNAZ is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.